Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia

Leukemia

Volumn 29, Issue 6, 2015, Pages 1243-1252

  Bochtler, T ^a   Frohling S ^b   Kramer A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; CANCER RECURRENCE; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CLONAL EVOLUTION; CLONAL VARIATION; CLONE; DISEASE COURSE; GENE DELETION; GENE DOSAGE; GENE INSERTION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MYELOID LEUKEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; CELL CLONE; GENETICS; PROGNOSIS;

CHROMOSOME ABERRATIONS; CLONE CELLS; GENETIC VARIATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS;

EID: 84930574013     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.32     Document Type: Review

References (114)

1. Jacobs PA, Court Brown WM, Doll R. Distribution of human chromosome counts in relation to age. Nature 1961; 191: 1178-1180.
2. Jacobs PA, Brunton M, Court Brown WM, Doll R, Goldstein H. Change of human chromosome count distribution with age: evidence for a sex differences. Nature 1963; 197: 1080-1081.
3. Galloway SM, Buckton KE. Aneuploidy and ageing: chromosome studies on a random sample of the population using G-banding. Cytogenet Cell Genet 1978; 20: 78-95.
4. Pierre RV, Hoagland HC. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer 1972; 30: 889-894.
5. Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11-16.
6. Loss of the Y chromosome from normal and neoplastic bone marrows. United Kingdom Cancer Cytogenetics Group (UKCCG). Genes Chromosomes Cancer 1992; 5: 83-88.
7. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet 2014; 46: 624-628.
8. Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012; 44: 642-650.
9. Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012; 44: 651-658.
10. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med 2008; 359: 722-734.
11. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-627.
12. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis. Gut 2008; 57: 941-950.
13. White BS, DiPersio JF. Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer 2014; 120: 1134-1144.
14. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-1133.
15. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011; 333: 1039-1043.
16. Sheltzer JM, Blank HM, Pfau SJ, Tange Y, George BM, Humpton TJ et al. Aneuploidy drives genomic instability in yeast. Science 2011; 333: 1026-1030.
17. Kolodner RD, Cleveland DW, Putnam CD. Cancer. Aneuploidy drives a mutator phenotype in cancer. Science 2011; 333: 942-943.
18. Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 2013; 155: 948-962.
19. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
20. Loeb LA, Springgate CF, Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res 1974; 34: 2311-2321.
21. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991; 51: 3075-3079.
22. Araten DJ, Golde DW, Zhang RH, Thaler HT, Gargiulo L, Notaro R et al. A quantitative measurement of the human somatic mutation rate. Cancer Res 2005; 65: 8111-8117.
23. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
24. Bakhoum SF, Compton DA. Chromosomal instability and cancer: A complex relationship with therapeutic potential. J Clin Invest 2012; 122: 1138-1143.
25. Janssen A, van der Burg M, Szuhai K, Kops GJ, Medema RH. Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science 2011; 333: 1895-1898.
26. Hunter A. High risk of malignancy in mosaic variegated aneuploidy syndrome. Am J Med Genet A 2003; 117A: 199.
27. Jacquemont S, Boceno M, Rival JM, Mechinaud F, David A. High risk of malignancy in mosaic variegated aneuploidy syndrome. Am J Med Genet 2002; 109: 17-21, discussion 16.
28. Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 2004; 36: 1159-1161.
29. Rio Frio T, Lavoie J, Hamel N, Geyer FC, Kushner YB, Novak DJ et al. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med 2010; 363: 2628-2637.
30. Nasmyth K. Segregating sister genomes: the molecular biology of chromosome separation. Science 2002; 297: 559-565.
31. Schockel L, Mockel M, Mayer B, Boos D, Stemmann O. Cleavage of cohesin rings coordinates the separation of centrioles and chromatids. Nat Cell Biol 2011; 13: 966-972.
32. Tsou MF, Wang WJ, George KA, Uryu K, Stearns T, Jallepalli PV. Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells. Dev Cell 2009; 17: 344-354.
33. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
34. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-1098.
35. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
36. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013; 45: 1232-1237.
37. Thol F, Bollin R, Gehlhaar M, Walter C, Dugas M, Suchanek KJ et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014; 123: 914-920.
38. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 2013; 45: 1293-1299.
39. Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 2014; 124: 1790-1798.
40. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
41. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
42. Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008; 35: 365-377.
43. Heilig CE, Loffler H, Mahlknecht U, Janssen JW, Ho AD, Jauch A et al. Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J Cell Mol Med 2010; 14: 895-902.
44. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3: 23-34.
45. Naim V, Rosselli F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nat Cell Biol 2009; 11: 761-768.
46. Meyer S, Neitzel H, Tonnies H. Chromosomal aberrations associated with clonal evolution and leukemic transformation in fanconi anemia: clinical and biological implications. Anemia 2012; 2012: 349837.
47. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101: 822-826.
48. Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pages MP et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 2011; 117: e161-e170.
49. Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B et al. Numerical chromosomal changes and risk of development of myelodysplastic syndrome-acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet 2010; 203: 180-186.
50. Poppe B, Van Limbergen H, Van Roy N, Vandecruys E, De Paepe A, Benoit Y et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet 2001; 128: 39-42.
51. Li Y, Li X, Ge M, Shi J, Qian L, Zheng Y et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience. Ann Hematol 2011; 90: 529-537.
52. Afable MG 2nd, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 90-95.
53. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129-3135.
54. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013.
55. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010; 304: 1358-1364.
56. Dumitriu B, Feng X, Ueda Y, Kajigaya S, Townsley D, Zsu J et al. Clonal Evolution In Aplastic Anemia Is Driven By Chromosomal Instability Rather Than Mutations In Myeloid Malignancy Candidate Gene. 55th ASH Annual Meeting and Exposition, plenary session 2013.
57. Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H et al. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010; 49: 260-269.
58. Calado RT, Regal JA, Hills M, Yewdell WT, Dalmazzo LF, Zago MA et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA 2009; 106: 1187-1192.
59. McClintock B. The Stability of Broken Ends of Chromosomes in Zea Mays. Genetics 1941; 26: 234-282.
60. DePinho RA. The age of cancer. Nature 2000; 408: 248-254.
61. Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM et al. In utero origin of t (8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002; 99: 3801-3805.
62. Stark B, Jeison M, Preudhomme C, Fenaux P, Ash S, Korek Y et al. Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins. Br J Haematol 2002; 118: 1082-1086.
63. Bateman CM, Colman SM, Chaplin T, Young BD, Eden TO, Bhakta M et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood 2010; 115: 3553-3558.
64. Kwong YL, Wong KF, Chan V, Chan CH. Persistence of AML1 rearrangement in peripheral blood cells in t(8;21). Cancer Genet Cytogenet 1996; 88: 151-154.
65. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789-4796.
66. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97: 7521-7526.
67. Feuring-Buske M, Haase D, Buske C, Hiddemann W, Wormann B. Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission. Leukemia 1999; 13: 386-392.
68. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014; 111: 2548-2553.
69. Greaves M. Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture. Hematology Am Soc Hematol Educ Program 2009, 3-12.
70. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
71. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
72. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
73. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148: 59-71.
74. Bernasconi P, Klersy C, Boni M, Cavigliano PM, Giardini I, Rocca B et al. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes A study on 153 patients from a single institution. Ann Hematol 2010; 89: 545-551.
75. Wang H, Wang XQ, Xu XP, Lin GW. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. Cancer Genet Cytogenet 2010; 196: 159-166.
76. Cordoba I, Gonzalez-Porras JR, Nomdedeu B, Luno E, de Paz R, Such E et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer 2012; 118: 127-133.
77. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820-829.
78. Shirneshan K, Platzbecker U, Nolte F, Giagounidis A, Götze K, Schlenk RF et al. Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response-, Evolutionary-, and Remission Patterns and No Increased Karyotype Evolution (KE). 55th ASH Annual Meeting and Exposition, plenary session 2013.
79. Bershteyn M, Hayashi Y, Desachy G, Hsiao EC, Sami S, Tsang KM et al. Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells. Nature 2014; 507: 99-103.
80. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
81. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
82. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
83. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741-3750.
84. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
85. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119: 2114-2121.
86. Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M et al. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 2014; 123: 2960-2967.
87. Bochtler T, Stolzel F, Heilig CE, Kunz C, Mohr B, Jauch A et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 2013; 31: 3898-3905.
88. Sawyer JR, Roloson GJ, Head DR, Becton D. Karyotype evolution in a patient with Down syndrome and acute leukemia following a congenital leukemoid reaction. Med Pediatr Oncol 1994; 22: 404-409.
89. Landau DA, Carter SL, Getz G, Wu CJ. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 2014; 28: 34-43.
90. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 2003; 102: 462-469.
91. Perrot A, Luquet I, Pigneux A, Mugneret F, Delaunay J, Harousseau JL et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: A GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 2011; 118: 679-685.
92. Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer 2014; 53: 402-410.
93. Paulsson K. Genomic heterogeneity in acute leukemia. Cytogenet Genome Res 2013; 139: 174-180.
94. Kronke J, Bullinger L, Teleanu V, Tschurtz F, Gaidzik VI, Kuhn MW et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122: 100-108.
95. Bacher U, Haferlach T, Alpermann T, Zenger M, Kroger N, Beelen DW et al. Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. Biol Blood Marrow Transplant 2010; 16: 1649-1657.
96. Garson OM, Hagemeijer A, Sakurai M, Reeves BR, Swansbury GJ, Williams GJ et al. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Cancer Genet Cytogenet 1989; 40: 187-202.
97. Schmidt-Hieber M, Blau IW, Richter G, Turkmen S, Bommer C, Thiel G et al. Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation. Cancer Genet Cytogenet 2010; 198: 135-143.
98. Ottone T, Zaza S, Divona M, Hasan SK, Lavorgna S, Laterza S et al. Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. Br J Haematol 2013; 161: 533-540.
99. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 149ra18.
100. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322: 1377-1380.
101. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.
102. Damm F, Markus B, Thol F, Morgan M, Gohring G, Schlegelberger B et al. TET2 mutations in cytogenetically normal acute myeloid leukemia: Clinical implications and evolutionary patterns. Genes Chromosomes Cancer 2014; 53: 824-832.
103. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T et al. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica 2012; 97: 1242-1245.
104. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39 (4 Suppl 3): 6-11.
105. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285-6295.
106. Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008; 35: 336-345.
107. Grove CS, Vassiliou GS. Acute myeloid leukaemia: A paradigm for the clonal evolution of cancer? Dis Model Mech 2014; 7: 941-951.
108. Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 2013; 121: 369-377.
109. Chen SJ, Shen Y, Chen Z. A panoramic view of acute myeloid leukemia. Nat Genet 2013; 45: 586-587.
110. Gohring G, Giagounidis A, Busche G, Kreipe HH, Zimmermann M, Hellstrom-Lindberg E et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010; 89: 365-374.
111. Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971-1979.
112. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19: 1405-1413.
113. Wong TN, Ramsingh G, Young A, Shen D, Miller C, Lamprecht T et al. The role of early TP53 mutations on the evolution of therapy-related AML. 55th ASH Annual Meeting and Exposition, plenary session 2013.
114. Anderhub SJ, Kramer A, Maier B. Centrosome amplification in tumorigenesis. Cancer Lett 2012; 322: 8-17.